Illumina (NASDAQ:ILMN) Stock Falls 6% – Here’s Why

Posted by Brian Himes on Oct 6th, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price was down 6% on Tuesday. The company traded as low as $275.03 and last traded at $276.1260. 1,628,854 shares traded hands during mid-day trading, a decline of 24% from the average daily volume of 2,151,239 shares. The stock had previously closed at $293.69.

Key Illumina News

Here are the key news stories impacting Illumina this week:

Positive Sentiment: RBC raised its price target to $310 from $230 and reaffirmed an “outperform” rating, citing improving fundamentals and potential upside from current levels. The upgrade helped push Illumina to a new one-year high. Royal Bank Of Canada Issues Positive Forecast for Illumina Stock Price
Positive Sentiment: RBC also described Illumina’s clinical sequencing revenue as a potentially durable mid-teens growth business, strengthening the outlook for recurring demand from hospitals, laboratories and pharmaceutical customers. Illumina’s Clinical Sequencing Revenue Seen as Durable Mid-Teens Grower
Positive Sentiment: Investors are increasingly viewing Illumina’s sequencing platforms as potential infrastructure for artificial-intelligence applications, while analysts anticipate improved clinical sales and additional growth catalysts. The company’s higher 2026 guidance and September addition to the S&P 500 have provided further momentum. Illumina Shares Skyrocket, What You Need to Know
Neutral Sentiment: The broader genomics sector also received attention after EpiSign and Geneyx announced a rare-disease analysis partnership incorporating PacBio sequencing data. The announcement supports industry-wide interest in genomic interpretation but has no direct financial impact on Illumina. EpiSign and Geneyx Announce Partnership
Negative Sentiment: Valuation and insider activity remain risks. Illumina trades at roughly 52 times earnings, while reported insider transactions show substantial selling and no open-market purchases over the past six months. This could limit upside if growth expectations weaken.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent analyst reports. Citigroup boosted their price objective on shares of Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a research report on Monday, August 3rd. Leerink Partners lifted their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Guggenheim boosted their price target on shares of Illumina from $226.00 to $305.00 and gave the company a “buy” rating in a research report on Thursday. Wall Street Zen lowered Illumina from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Barclays lifted their target price on Illumina from $145.00 to $160.00 and gave the stock an “underweight” rating in a research report on Friday, July 31st. Ten research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus price target of $219.69.

View Our Latest Stock Analysis on ILMN

Illumina Stock Down 5.6%

The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The firm’s 50 day moving average price is $221.46 and its two-hundred day moving average price is $177.17. The firm has a market cap of $41.86 billion, a price-to-earnings ratio of 51.72, a P/E/G ratio of 3.87 and a beta of 1.41.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the business earned $1.19 EPS. The firm’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last ninety days, insiders have sold 2,061,850 shares of company stock worth $436,479,102. 2.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in Illumina during the second quarter worth approximately $3,374,423,000. Plato Investment Management Ltd acquired a new stake in shares of Illumina during the 2nd quarter worth $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Illumina during the 2nd quarter worth $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new position in shares of Illumina in the 2nd quarter worth $129,792,000. Finally, Impact Partnership Wealth LLC boosted its holdings in Illumina by 235.8% in the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock valued at $1,366,000 after acquiring an additional 7,780 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

(Get Free Report)

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.